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Summary 
Both Leishmania promastigote and amastigote forms synthesize complex 
glycoconjugates which are either displayed on their surface and that have been 
shown to play important roles in parasite virulence both in the sandfly and the 
mammalian host, or are excreted-secreted. Due to their location or because they are 
released into the host environment, these excreted-secreted antigens (ESA) are the 
first to establish a close contact with the immune system of the host modulating its 
functions. Previous studies have demonstrated that antigens secreted by 
microorganisms can quickly bind to class-I and -II molecules of major 
histocompatibility complex priming CD4+ and CD8+ T lymphocytes. In contrast, 
somatic antigens, encapsulated by cellular membranes and protected from the 
antigen processing machinery of eukaryotic cells, are only processed after pathogen 
destruction, leading to a delay in the T cell stimulation. Antigens released from 
promastigote forms have been identified as potent modulators of the immune system, 
having a crucial role in promoting the establishment and maintenance of the infection 
by interfering in the activation of effector mechanisms, such as the microbicidal 
activity of macrophages and cytokine production. Moreover, interesting studies using 
released antigens from Leishmania sp. as a model for the development of affordable 
vaccines have been conducted. The above considerations support the hypothesis 
that antigens released by Leishmania species may have potential to induce host 
protection and be used for vaccine development against leishmaniasis. The present 
work exposes our study strategy of Leishmania ESA, their production and their 
tremendous potential either as vaccine candidate of first generation and as a rich 
pool of other vaccine generations. From the successfully development of a 
completely defined serum-free medium that readily supports the continuous in vitro 
cultivation of promastigotes of most Leishmania species, we have been access to 
antigens naturally excreted-secreted by parasites, thus opening up a great 
opportunity to easily study them. The biological potential of these ESA is showed by 
our studies using of these naturally excreted-secreted antigens as a vaccine 
candidate of first generation, inducing a long-lasting and strong protective effect 
against canine visceral leishmaniasis, and as a rich source of major immunogenic 
antigens, conducting to new prospects to gain access to new vaccine generations for 
human use. 
 
